PFS Partners’s Charles River Laboratories CRL Stock Holding History

PFS Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-14	Closed	-$2.11K	–	509
2025 Q1	$2.11K	Hold	14	–	–	﹤0.01%	389
2024 Q4	$2.58K	Hold	14	–	–	﹤0.01%	387
2024 Q3	$2.76K	Hold	14	–	–	﹤0.01%	385
2024 Q2	$2.89K	Hold	14	–	–	﹤0.01%	370
2024 Q1	$3.79K	Hold	14	–	–	﹤0.01%	375
2023 Q4	$3.31K	Hold	14	–	–	﹤0.01%	380
2023 Q3	$2.74K	Hold	14	–	–	﹤0.01%	385
2023 Q2	$2.94K	Hold	14	–	–	﹤0.01%	399
2023 Q1	$2.83K	Hold	14	–	–	﹤0.01%	314
2022 Q4	$3.05K	Hold	14	–	–	﹤0.01%	296
2022 Q3	$2.76K	Hold	14	–	–	﹤0.01%	290
2022 Q2	$3K	Hold	14	–	–	﹤0.01%	279
2022 Q1	$3.98K	Hold	14	–	–	﹤0.01%	272
2021 Q4	$5.28K	Buy	+14	New	+$5.44K	﹤0.01%	257

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

PFS Partners's CRL Position: Q2 2025 in Review

PFS Partners sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 14 shares — an estimated $2.11K sold.

PFS Partners first reported a position in CRL in Q4 2021 and held it in 14 quarters. The position peaked at $5.28K in Q4 2021. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

PFS Partners reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
PFS Partners sold 14 Charles River Laboratories shares in Q2 2025, an estimated $2.11K.
PFS Partners first reported a position in Charles River Laboratories in Q4 2021 and held it in 14 quarters.
PFS Partners's Charles River Laboratories position peaked at $5.28K in Q4 2021.
519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on PFS Partners's 13F filing for Q2 2025, filed 16 Jul 2025.